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Non-Cognitive Predictors of Student Success:
A Predictive Validity Comparison Between Domestic and International Students
In a single-center, high-volume 
TAVR program, fewer ischemic 
neurological events occurred 
after adoption of Sentinel for all 
anatomically- and clinically-
appropriate patients.• Sentinel device is approved for cerebral embolic protection (CEP) during transcatheter aortic valve replacement 
(TAVR)
• Randomized clinical trails evaluating the impact of CEP on 
peri-procedural neurologic events are largely inconclusive 
and underpowered1,2
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Objective: Evaluate the real-world impact of our high-
volume TAVR program’s decision to use CEP in all 
transfemoral patients without an anatomic or clinical 
contraindication.
Methods
• Retrospective analysis of all patients who underwent 
transfemoral TAVR for one year after CEP implementation 
on 10/15/2018, compared to one year prior
• Primary outcome was peri-procedural (within 3 days) 
ischemic stroke and transient ischemic attack (TIA)
• Secondary outcomes included procedural outcomes and 
peri-procedural (within 3 days) hemorrhagic stroke, 
mortality, life threatening or major bleeding, major vascular 
complications, and new dialysis
• Chi-square test or Fisher exact test was used to compare 
events pre- and post-CEP implementation
• In our program, adoption of a strategy utilizing cerebral embolic 
protection in all anatomically and clinically suitable TAVR patients was 
associated with fewer ischemic neurological events. 
• The Sentinel device was used in 57% of all patients undergoing 
transfemoral TAVR, and was associated with an increase in procedure 
time and fluoroscopy time of 9.0 and 3.4 minutes, respectively.
Results
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Female 148 (50.3) 131 (44.6) 0.16 55 (43.7) 76 (45.2) 0.786












Prior PAD 55 (18.7) 85 (28.9) 0.004 51 (40.5) 34 (20.2) <0.001
Prior stroke 32 (10.9) 34 (11.6) 0.794 10 (7.9) 24 (14.3) 0.092
Prior TIA 21 (7.1) 31 (10.5) 0.146 16 (12.7) 15 (8.9) 0.298
Prior CABG 41 (13.9) 49 (16.7) 0.36 26 (20.6) 23 (13.7) 0.114
Prior AV surgery 32 (10.9) 43 (14.7) 0.169 18 (14.3) 25 (15.0) 0.870






































Table 1: Patient and Procedural Characteristics
Data presented as median (IQR) or n (%)
BMI = body mass index, CABG = coronary artery bypass graft, CEP = cerebral embolic protection, ICU = intensive care unit, LOS = length of stay, 
NYHA = New York Heart Association, PAD = peripheral artery disease, STS =Society of Thoracic Surgeons, TIA = transient ischemic attack, TAVR 





























10 (3.4%) 2 (0.7%) 0.037 0 (0.0%) 2 (1.2%) 0.509
Ischemic stroke 7 (2.4) 1 (0.3) 0.068 0 (0.0) 1 (0.6) >0.999
TIA 3 (1.0) 1 (0.3) 0.624 0 (0.0) 1 (0.6) >0.999
Hemorrhagic 
stroke
0 (0.0) 0 (0.0) N/A 0 (0.0) 0 (0.0) N/A
Major/life-
threatening bleed
0 (0.0) 2 (0.7) 0.499 1 (0.8) 1 (0.6) >0.999
Major VC 10 (3.4) 9 (3.1) 0.816 6 (4.8) 3 (1.8) 0.179
New dialysis 1 (0.4) 1 (0.4) >0.999 1 (0.8) 0 (0.0) 0.419
Mortality 0 (0.0) 1 (0.3) >0.999 1 (0.8) 0 (0.0) 0.429
Table 2: Peri-procedural Outcomes
• Among the 168 patients with CEP device, there were 4 (2.4%) partial deployments
• One ischemic stroke occurred in the left-sided circulation in a CEP patient in whom 
only the innominate filter could be deployed 
